Stem cell transplantation for multiple myeloma: current and future status

References

• McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma cell leukemia and myeloma. Lancet. 1983;2(8354):822–4.
   PubMed Web of Science ®Google Scholar
• Selby P, McElwain TJ, Nandi AC, Perren TJ, Powles RL, Tillyer CR, et al.. Multiple myeloma treated with high dose intravenous melphalan. Br J Hematol. 1987;66:55–62.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67:1298–301.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, et al.. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70:869–72.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood. 1994;84:4278–82.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al.. A prospective randomized trial of Autologous Bone Marrow Transplantation and chemotherapy in Multiple Myeloma. N Engl J Med. 1996;335:91–7.
   PubMed Web of Science ®Google Scholar
• Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al.. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92(9):3131–6.
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al.. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–83.
   PubMed Web of Science ®Google Scholar
• Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J, et al.. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005;106(12):3755–9.
   PubMed Web of Science ®Google Scholar
• Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al.. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23(36):9227–33.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al.. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24(6):929–36.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hassoun H, Hurd DD, et al.. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplantation for multiple myeloma: CALGB 100104. Blood. 2010;116:abstract 37.
   Web of Science ®Google Scholar
• Chanan-Khan A, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28:2612–24.
   PubMed Web of Science ®Google Scholar
• Macro M, Divine M, Uzunhan Y, Jaccard A, Bouscary D, Leblond V, et al.. Dexamethasone thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. Blood. 2006;108:22a (abstract 57).
   Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al.. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376:2075–85.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al.. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28:4621–9.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf IGH, Van der Holt B, Bertsch U, Jarari EIL, Salwender H, et al.. HOVON-65/GMMG-HD4 Randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high dose melphalan and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma. Blood. 2010;116:abstract 40.
   Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al.. Lenalidomide plus high dose dexamethasone versus lenalidomide plus low dose dexamethasone as initial therapy for newly diagnosed multiple myeloma; an open label randomized controlled trial. Lancet Oncol. 2010;11:29–37.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Jacobus S, Rajkumar VS, Abonour R, Callander NS, Katz MS, et al.. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in the ECOG E4A03 randomized clinical trial. Blood. 2010;116:38.
   Google Scholar
• NCCN Guidelines for Myeloma. Version 1–2011. www.nccn.org
   Google Scholar
• Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al.. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679–86.
   PubMed Web of Science ®Google Scholar
• Kumar S, Flinn IW, Richardson PG, et al.. Novel three- and four drug combination regimens of bortezomib, dexamethasone, cyclophosphamide and lenalidomide for previously untreated multiple myeloma: results from the multi center, randomized phase 2 EVOLUTION study. Blood. 2010;116:abstract 621.
   Google Scholar
• Hahn T, Wingard J, Anderson K, et al.. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant. 2003;9:4–37.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al.. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789–93.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al.. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–502.
   PubMed Web of Science ®Google Scholar
• Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al.. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434–41.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al.. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289–94.
   PubMed Web of Science ®Google Scholar
• Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, et al.. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009;27:1788–93.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, et al.. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010;115:1113–20.
   PubMed Web of Science ®Google Scholar
• Morgan G, Jackson GH, Davies FE, Drayson MT, Owen RG, Gregory WM, et al.. Maintenance thalidomide may improve progression free but not overall survival; results from the Myeloma IX maintenance randomisation. Blood. 2008;112:abstract 656.
   Web of Science ®Google Scholar
• Attal M, Olivier P, Cances Lauwers V, Marit G, Caillot D, Facon T, et al.. Maintenance treatment with lenalidomide after transplantation for myeloma. Analysis of secondary malignancies within the IFM 2005-02 trial. Haematologica 2011;96(Suppl 1);s23.
   Google Scholar
• McCarthy P, Owzar K, Anderson K, Hofmeister CC, Hassoun H, Hurd DD, et al.. Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB, ECOG, BMT CTN 100104. Haematologica. 2011;96:(Suppl 1)s23.
   Google Scholar
• Cavo M, Rajkumar V, Palumbo A, Moreau P, Orlowski R, Bladé J, et al.. International Myeloma Working Group (IMWG) consensus approach to the treatment of multiple myeloma who are candidates for autologous stem cell transplantation. Blood. 2011;117(23):6063–73.
   PubMed Web of Science ®Google Scholar